![]() |
|
![]() |
|
Names | |
---|---|
IUPAC name
Ethyl carbamate
|
|
Other names
Urethane
|
|
Identifiers | |
51-79-6 ![]() |
|
3D model (Jmol) |
Interactive image Interactive image |
3DMet | B00312 |
ChEBI |
CHEBI:17967 ![]() |
ChEMBL |
ChEMBL462547 ![]() |
ChemSpider |
5439 ![]() |
DrugBank |
DB04827 ![]() |
ECHA InfoCard | 100.000.113 |
EC Number | 200-123-1 |
KEGG |
C01537 ![]() |
MeSH | Urethane |
PubChem | 5641 |
RTECS number | FA8400000 |
UNII |
3IN71E75Z5 ![]() |
UN number | 2811 |
|
|
|
|
Properties | |
C3H7NO2 | |
Molar mass | 89.09 g·mol−1 |
Appearance | White crystals |
Density | 1.056 g cm−3 |
Melting point | 46 to 50 °C (115 to 122 °F; 319 to 323 K) |
Boiling point | 182 to 185 °C (360 to 365 °F; 455 to 458 K) |
0.480 g cm−3 at 15 °C | |
log P | -0.190(4) |
Vapor pressure | 1.3 kPa at 78 °C |
Acidity (pKa) | 13.58 |
0.5206015862 D | |
Hazards | |
Main hazards | Harmful if swallowed May cause cancer |
EU classification (DSD)
|
![]() |
R-phrases | R45 |
S-phrases | S45, S53 |
NFPA 704 | |
Flash point | 92 °C (198 °F; 365 K) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
![]() ![]() ![]() |
|
Infobox references | |
May cause cancer
Ethyl carbamate (also called urethane) is a chemical compound with the molecular formula C3H7NO2 first prepared in the nineteenth century. Structurally, it is an ester of carbamic acid. Despite its common name, it is not a component of polyurethanes.
Ethyl carbamate is a white crystalline substance produced by heating urea nitrate and ethyl alcohol or by the action of ammonia on ethyl chloroformate.
Ethyl carbamate has been produced commercially in the United States for many years. It has been used as an antineoplastic agent and for other medicinal purposes but this ended after it was discovered to be carcinogenic in 1943. However, Japanese usage in medical injections continued and from 1950 to 1975 an estimated 100 million 2 ml ampules of 7 to 15% solutions of ethyl carbamate were injected into patients as a co-solvent in water for dissolving water-insoluble analgesics used for post-operation pain. These doses were estimated by Nomura (Cancer Research, 35, 2895–2899, October 1975) to be at levels that are carcinogenic in mice. This practice was stopped in 1975. "This regrettable medical situation appears to have involved the largest number (millions) of humans exposed to the largest doses of a pure carcinogen that is on record" (Japanese Journal of Cancer Research, 82, 1323–1324, December 1991). The author, U.S. cancer researcher James A. Miller, called for studies to determine the effects on Japanese cancer rates to be performed but apparently none were ever done.
Prior to World War II, ethyl carbamate saw relatively heavy use in the treatment of multiple myeloma before it was found to be toxic, carcinogenic and largely ineffective. By US FDA regulations, ethyl carbamate has been withdrawn from pharmaceutical use. However, small quantities of ethyl carbamate are also used in laboratories as an anesthetic for animals.
Ethyl carbamate was upgraded to a Group 2A carcinogen by IARC in 2007.
Formerly, crosslinking agents for permanent press textile treatments were synthesized from ethyl carbamate.